Hong Kong – October 13, 2026 -- Fosun International (HKEX: 00656) won five awards at The Asset Corporate Sustainability Leadership Awards 2026, moving up from Gold to the Platinum Award in the main category.

The Hong Kong-listed group also took four single-category prizes: Best in Disclosure & Transition, Best Initiative in Environmental Responsibility, Best Initiative in Social Responsibility and Best Sustainability Team. The Asset is an Asia-Pacific financial publication.

Hong Kong – October 08, 2026 -- Sisram Medical Ltd (1696.HK) has announced a share repurchase plan to buy back up to 1% of its total issued shares on the open market, citing confidence in its long-term growth trajectory.

Hod Hasharon, Israel & Shanghai – September 07, 2026 -- Raziel Therapeutics and Fosun Pharma reported that RZL-012, an injectable lipolytic drug for submental fat reduction, met every primary and secondary endpoint in a 480-patient Phase 3 trial in China, with the primary responder rate outperforming placebo by 30 percentage points after a single treatment cycle.

HONG KONG -- September 01, 2026 -- Fosun International reported a 160.3% year-on-year surge in first-half profit attributable to owners of the parent to RMB1.72 billion, the conglomerate said at an interim results presentation held in Hong Kong on Aug. 28. Total revenue for the six-month period reached RMB86.96 billion, with overseas markets contributing RMB49.16 billion, or 56.5% of the total.